PDS Biotechnology Corp Restructuring Charges
PDS Biotechnology Corp (PDSB) reported Restructuring Charges of $2.07 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2020-03-27
- PDS Biotechnology Corp restructuring charges for the quarter ending 2019-03-31 was $121.67K.
- PDS Biotechnology Corp restructuring charges for the quarter ending 2018-12-31 was $2.42M.
- PDS Biotechnology Corp restructuring charges for the quarter ending 2018-09-30 was $847.85K.
- PDS Biotechnology Corp restructuring charges for the quarter ending 2018-06-30 was $6.65M.
- PDS Biotechnology Corp restructuring charges for fiscal 2019 was $2.07M, a 79.12% decline from fiscal 2018.
- PDS Biotechnology Corp restructuring charges for fiscal 2018 was $9.91M.
- PDS Biotechnology Corp restructuring charges for fiscal 2017 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2019-12-31 | $2.07M 10-K · filed 2020-03-27 | |||
| 2019-03-31 | $121.67K 10-Q · filed 2019-05-14 | $2.54M derived: sum of 2 quarters · filed 2019-05-14 | $3.39M derived: sum of 3 quarters · filed 2019-05-14 | $10.04M derived: sum of 4 quarters · filed 2019-05-14 |
| 2018-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $3.27M derived: sum of 2 quarters · filed 2019-02-21 | $9.91M derived: sum of 3 quarters · filed 2019-02-21 | $9.91M 10-K · filed 2019-02-21 |
| 2018-09-30 | $847.85K 10-Q · filed 2018-11-01 | $7.49M derived: sum of 2 quarters · filed 2018-11-01 | $7.49M 10-Q · filed 2018-11-01 | $7.49M derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-06-30 | $6.65M 10-Q · filed 2018-08-01 | $6.65M 10-Q · filed 2018-08-01 | $6.65M derived: sum of 3 quarters · filed 2019-02-21 | $6.65M derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2019-02-21 | $0.00 derived: sum of 2 quarters · filed 2019-02-21 | $0.00 derived: sum of 3 quarters · filed 2019-02-21 | $0.00 derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $0.00 derived: sum of 2 quarters · filed 2019-02-21 | $0.00 derived: sum of 3 quarters · filed 2019-02-21 | $0.00 10-K · filed 2019-02-21 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-01 | $0.00 10-Q · filed 2018-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |